Search research articles
Contact Us
Filters
Showing results (511-520 of 1,058) with videos related to
Page
of 106
Sort By:
Blood
|
September 1, 2007
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
Qing Liu, Xiaobin Zhao, Frank Frissora, et al.
Blood
|
May 4, 2006
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
Amy J Johnson, David M Lucas, Natarajan Muthusamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2013
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol
Jia Ji, Diane R Mould, Kristie A Blum, et al.
Cancer Chemotherapy and Pharmacology
|
March 1, 2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
Jan de Jong, Juthamas Sukbuntherng, Donna Skee, et al.
Cancers
|
June 18, 2020
Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
Lindsey T Brinton, Steven Sher, Katie Williams, et al.
Blood
|
November 25, 2003
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Andrew P Mone, Peng Huang, Helene Pelicano, et al.
Blood
|
July 13, 2000
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
I W Flinn, J C Byrd, C Morrison, et al.
British Journal of Haematology
|
October 24, 2007
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia
Amy J Johnson, Amy J Wagner, Carolyn M Cheney, et al.
Blood
|
June 26, 2004
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Thomas S Lin, Ian W Flinn, Rama Modali, et al.
Cancer
|
August 8, 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701
Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, et al.
Page
of 106
Search research articles
Search
Showing results (511-520 of 1,058) with videos related to
Sort By:
Page
of 106
Blood
|
September 1, 2007
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
Qing Liu, Xiaobin Zhao, Frank Frissora, et al.
Blood
|
May 4, 2006
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
Amy J Johnson, David M Lucas, Natarajan Muthusamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 10, 2013
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol
Jia Ji, Diane R Mould, Kristie A Blum, et al.
Cancer Chemotherapy and Pharmacology
|
March 1, 2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
Jan de Jong, Juthamas Sukbuntherng, Donna Skee, et al.
Cancers
|
June 18, 2020
Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
Lindsey T Brinton, Steven Sher, Katie Williams, et al.
Blood
|
November 25, 2003
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Andrew P Mone, Peng Huang, Helene Pelicano, et al.
Blood
|
July 13, 2000
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
I W Flinn, J C Byrd, C Morrison, et al.
British Journal of Haematology
|
October 24, 2007
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia
Amy J Johnson, Amy J Wagner, Carolyn M Cheney, et al.
Blood
|
June 26, 2004
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Thomas S Lin, Ian W Flinn, Rama Modali, et al.
Cancer
|
August 8, 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701
Barbara W Grant, Sin-Ho Jung, Jeffrey L Johnson, et al.
Page
of 106